Table 2.

Logistic regression analysis of the relationship between TBX21 expression and clinical factors.

Clinical factors		Total (N)	OR (95% CI)	P-value
Age (years)	≥58 vs. <58	445	0.9221 (0.6349–1.3386)	0.6697
Gender	Male vs. Female	445	0.7841 (0.5358–1.1456)	0.2093
Stage	II vs. I	216	0.4567 (0.2570–0.8031)	0.0069
	III vs. I	246	0.8784 (0.5062–1.5138)	0.6419
	IV vs. I	99	0.9455 (0.3694–2.4707)	0.9071
T stage	T2 vs. T1	119	0.4643 (0.2053–1.0122)	0.0581
	T3 vs. T1	131	0.5306 (0.2383–1.1380)	0.1101
	T4 vs. T1	193	0.3469 (0.1624–0.7089)	0.0046
Lymph nodes	N1 vs. N0	308	1.0320 (0.6104–1.7424)	0.9062
	N2 vs. N0	283	1.3369 (0.7214–2.5003)	0.3577
	N3 vs. N0	288	1.3616 (0.7526–2.4855)	0.3092
Distant metastasis	M1 vs. M0	440	1.1932 (0.5218–2.7760)	0.6749

TBX21 – T-box transcription factor protein 21; OR – odds ratio; CI – confidence interval. P<0.05 was considered statistically significant, and P-value less than 0.05 in the table are shown in bold; the median age at diagnosis was 58 years old.